OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer.
NPJ Breast Cancer
; 7(1): 27, 2021 Mar 17.
Article
in En
| MEDLINE
| ID: mdl-33731699
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
NPJ Breast Cancer
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: